Evidence map›Paper›PMID 28421464›Full record

ArticleEndocrine pathology2017

A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma.

Daniel Bulzico, Davi Coe Torres, Gerson Moura Ferreira, Bruno Ricardo Barreto Pires, Paulo Antônio Silvestre de Faria, Rocio Hassan, Eliana Abdelhay, Mario Vaisman, Leonardo Vieira Neto

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Daniel BulzicoEndocrine Oncology Unit, Brazilian National Cancer Institute-INCA, Praça da Cruz Vermelha, 23, 8th floor, Rio de Janeiro/RJ, CEP 20.230-130, Brazil. danielbulzico@gmail.com.ORCID http://orcid.org/0000-0003-1270-7241
Davi Coe TorresLaboratory of Oncovirology, Center for Bone Marrow Transplants, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil.
Gerson Moura FerreiraStem Cell Laboratory, Center for Bone Marrow Transplants, Brazilian National Cancer Institute - INCA, Rio de Janeiro, Brazil.
Bruno Ricardo Barreto PiresStem Cell Laboratory, Center for Bone Marrow Transplants, Brazilian National Cancer Institute - INCA, Rio de Janeiro, Brazil.
Paulo Antônio Silvestre de FariaDivision of Pathology, Brazilian National Cancer Institute - INCA, Rio de Janeiro, Brazil.
Rocio HassanLaboratory of Oncovirology, Center for Bone Marrow Transplants, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil.
Eliana AbdelhayStem Cell Laboratory, Center for Bone Marrow Transplants, Brazilian National Cancer Institute - INCA, Rio de Janeiro, Brazil.
Mario VaismanDepartment of Internal Medicine and Endocrinology Section-Medical School and Clementino Fraga Filho University Hospital, Rio de Janeiro Federal University, Rio de Janeiro, Brazil.
Leonardo Vieira NetoEndocrinology Section, Federal Hospital of Lagoa, Rio de Janeiro, Brazil.
Instituto Nacional de Câncer - INCA · BRHospital Universitário Clementino Fraga Filho · BRHospital Santa Luzia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinomas (ACC) are very rare tumors related to TP53 mutations mostly in childhood onset cases. Epithelial-mesenchymal transition (EMT) transcription factors TWIST1 and Smad interacting protein 1 (SIP1) are related to poorer outcomes in other malignancies, but their role in ACC is unknown. We describe a case of an advanced metastatic ACC (Weiss-score of 9) in a patient at age 76. After primary tumor resection, mitotane therapy was started as palliation to low-volume liver metastasis. After a 2-year period of stable disease, the patient died due to brain metastasis. Somatic gene sequencing revealed a novel TP53 mutation in DNA extracted from paraffin-embedded tissue, a deletion of 8bp in exon 8 (c.811_818del8; GAGGTGCG/-) in homo or hemizygosis causing a subsequent frameshift and premature stop codon at position 302. Immunohistochemistry of P53 and p-Ser-15 P53 showed absent tumoral staining. In addition, immunohistochemical analysis showed an increased expression of the mesenchymal markers vimentin and fibronectin. At last, EMT transcription factors TWIST1 and SIP1 were also overexpressed in tumoral cells. This case report describes an aggressive ACC with not only a novel somatic mutation, but also a novel International Agency for Research on Cancer database 8 base-pair deletion in TP53 exon 8. In addition, the expression of EMT inducers TWIST1 and SIP1 have been reported for the first time in an ACC case. Further investigation is needed to clarify the biologic significance of this new TP53 mutation and its role in the EMT process.

Indexed as

Adrenocortical CarcinomaAgedEpithelial-Mesenchymal TransitionFemaleHumansMutationNerve Tissue ProteinsNuclear ProteinsRNA-Binding ProteinsTumor Suppressor Protein p53Twist-Related Protein 1GEMIN2 protein, humanNerve Tissue ProteinsNuclear ProteinsRNA-Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53TWIST1 protein, humanTwist-Related Protein 1Adrenocortical carcinomaMutationSIP1TP53TWIST1

Identifiers

PMID28421464
OpenAlexW2605734664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.